PuSH - Publication Server of Helmholtz Zentrum München: Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Bonadonna, R.C.* ; Renard, E.* ; Cheng, A.-L.* ; Fritsche, A. ; Cali, A.* ; Melas-Melt, L.* ; Umpierrez, G.E.*

Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?

Diabetes Res. Clin. Pract. 142, 19-25 (2018)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Aims: To assess the impact of duration of prior basal insulin therapy on study outcomes in people with type 2 diabetes mellitus receiving insulin glargine 300 U/mL (Gla-300) or insulin glargine 100 U/mL (Gla-100) for 6 months.Methods: A post hoc patient-level meta-analysis of data from the EDITION 1 and 2 studies. Outcomes included: HbA1c, percentage of participants with >= 1 confirmed or severe hypoglycaemic event at night (00: 00-05: 59 h) or any time (24 h), and body weight change. Data were analysed according to duration of prior basal insulin use: >0-<= 2 years, >2-<= 5 years, >5 years.Results: This meta-analysis included 1618 participants. HbA(1c) change from baseline to month 6 was comparable between Gla-300 and Gla-100 groups, regardless of duration of prior basal insulin therapy. The lower risk with Gla-300 versus Gla-100 of >= 1 confirmed (<= 3.9 mmol/L [<= 70 mg/dL]) or severe hypoglycaemic event, at night or any time (24 h), was unaffected by duration of prior basal insulin therapy. Similarly, weight change was unaffected by duration of prior basal insulin therapy.Conclusions: Switching to Gla-300 from other basal insulin therapies provided comparable glycaemic control with lower risk of hypoglycaemia versus Gla-100, regardless of duration of prior basal insulin therapy.Clinical trial registration: NCT01499082, NCT01499095 (ClinicalTrials. gov).

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

2.548

1.445